230 related articles for article (PubMed ID: 33780038)
21. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
[No Abstract] [Full Text] [Related]
23. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Couturier MA; Thomas X; Raffoux E; Huguet F; Berthon C; Simand C; Gallego-Hernanz MP; Hicheri Y; Hunault Berger M; Saillard C; Leguay T; Loiseau C; Béné MC; Chevallier P
Leuk Lymphoma; 2021 Mar; 62(3):620-629. PubMed ID: 33153370
[TBL] [Abstract][Full Text] [Related]
24. The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Zhang Y; Qian JJ; Shen YJ; Hang SJ; Jin J; Zhu HH
Ann Hematol; 2022 May; 101(5):1141-1144. PubMed ID: 34661714
[No Abstract] [Full Text] [Related]
25. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
26. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
28. Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study.
Tavitian S; Uzunov M; Bérard E; Bouscary D; Thomas X; Raffoux E; Leguay T; Gallego Hernanz MP; Berceanu A; Leprêtre S; Hicheri Y; Chevallier P; Bertoli S; Lhéritier V; Dombret H; Huguet F
Leuk Lymphoma; 2020 Sep; 61(9):2161-2167. PubMed ID: 32508181
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
30. Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
Renzi D; Marchesi F; De Angelis G; Elia L; Salvatorelli E; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Arcese W; Mengarelli A;
Chemotherapy; 2017; 62(1):58-61. PubMed ID: 27618144
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
33. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G
Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681
[TBL] [Abstract][Full Text] [Related]
34. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy analysis of Venetoclax combined with TKI and dexamethasone-containing low-dose chemotherapy for relapsed/refractory Ph
Tian Y; Ai H; Ji X; Wei XD; Song YP; Yin QS
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):745-748. PubMed ID: 35280020
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Hampel PJ; Parikh SA; Call TG; Shah MV; Bennani NN; Al-Kali A; Rabe KG; Wang Y; Muchtar E; Leis JF; Kenderian SS; Koehler AB; Schwager SM; Slager SL; Kay NE; Hanson CA; Van Dyke DL; Shi M; Ding W
Blood Cancer J; 2021 Mar; 11(3):47. PubMed ID: 33654067
[No Abstract] [Full Text] [Related]
37. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
[No Abstract] [Full Text] [Related]
38. Experience with ponatinib in paediatric patients with leukaemia.
Rossoff J; Huynh V; Rau RE; Macy ME; Sulis ML; Schultz KR; Burke MJ; Athale U; O'Brien MM; Gregory JJ; van der Sluis IM; Keller FG; Zwaan CM; Suttorp M; Hijiya N
Br J Haematol; 2020 Apr; 189(2):363-368. PubMed ID: 31975387
[TBL] [Abstract][Full Text] [Related]
39. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Menna P; De Grazia U; Marchesi F; Minotti G; Salvatorelli E
Chemotherapy; 2020; 65(1-2):35-41. PubMed ID: 32829325
[TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
